Summary:
The main purpose of this study is to see whether TNX-102 SL can help people with fibromyalgia (FM). TNX-102 SL is the drug cyclobenzaprine in a new sublingual formulation, which means it is designed to be placed under the tongue and allowed to dissolve there
Qualified Participants Must:
• Participants must be Male or Female 18 to 65 years of age and have a diagnosis of primary FM.
Qualified Participants May Receive:
If you qualify, you may receive investigational medication and study-related procedures from a local doctor. Reimbursement for time and travel related to study participation may be provided.